Home › Funds › ORBIMED ADVISORS LLC › CGON
ORBIMED ADVISORS LLC position in CGON
CG ONCOLOGY INC · Health Care
ORBIMED ADVISORS LLC reported holding 972,800 shares of CGON (CG ONCOLOGY INC) in its Q2 2026 13F filing — a position valued at US$69.1M, representing 1.39% of its reported portfolio and ranking #19 among its reported holdings. ORBIMED ADVISORS LLC has disclosed CGON holdings in 8 of the last 8 reported quarters, going back to Q3 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ORBIMED ADVISORS LLC's CGON position evolved
ORBIMED ADVISORS LLC first disclosed a stake in CGON in Q3 2024 at 691,114 shares (US$26.1M). The position peaked in Q3 2025 at 1,726,850 shares, worth US$69.6M. Across 8 filings, ORBIMED ADVISORS LLC increased the stake 4 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 972,800 shares valued at US$69.1M — an increase of 24,533 shares quarter over quarter.. Notable position changes include a 107% increase in Q4 2024 (shares fell 15% over the following quarter), a 94% trim in Q2 2025 (shares rose 55% over the following quarter), a 1051% increase in Q3 2025 (shares rose 3% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2024 | 691.11K | $26.08M | New |
| Q4 2024 | 1.43M | $41.04M | Add |
| Q1 2025 | 2.47M | $60.54M | Add |
| Q2 2025 | 150.00K | $3.90M | Reduce |
| Q3 2025 | 1.73M | $69.56M | Add |
| Q4 2025 | 1.52M | $62.97M | Reduce |
| Q1 2026 | 948.27K | $64.18M | Reduce |
| Q2 2026 | 972.80K | $69.12M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CGON and 13F data
CGON (CG ONCOLOGY INC) is a Health Care company. 52 other funds we track also report a position in CGON — the largest reported positions include RTW INVESTMENTS, LP (US$605.0M), Decheng Capital LLC (US$452.7M), TCG Crossover Management, LLC (US$260.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CGON
- RTW INVESTMENTS, LP 8.51M sh · $604.96M · Q2 2026
- Decheng Capital LLC 6.37M sh · $452.71M · Q2 2026
- TCG Crossover Management, LLC 3.67M sh · $260.77M · Q2 2026
- Foresite Capital Management VI LLC 2.37M sh · $168.36M · Q2 2026
- Seven Fleet Capital Management LP 1.89M sh · $134.02M · Q2 2026
- DV Trading LLC 1.44M sh · $102.27M · Q2 2026
- Avidity Partners Management LP 1.40M sh · $99.40M · Q2 2026
- ACORN CAPITAL ADVISORS, LLC 1.13M sh · $80.39M · Q2 2026
- Foresite Capital Management V, LLC 1.08M sh · $76.67M · Q2 2026
- Logos Global Management LP 1.00M sh · $71.05M · Q2 2026
- Jefferies Financial Group Inc. 769.95K sh · $54.70M · Q2 2026
- EcoR1 Capital, LLC 561.50K sh · $39.89M · Q2 2026
More on ORBIMED ADVISORS LLC
FAQ
How long has ORBIMED ADVISORS LLC held CGON?
ORBIMED ADVISORS LLC has disclosed CGON holdings in 8 of the last 8 reported quarters, going back to Q3 2024.
What is ORBIMED ADVISORS LLC's current position in CGON?
As of Q2 2026, ORBIMED ADVISORS LLC holds 972.80K shares of CGON (CG ONCOLOGY INC), valued at $69.12M, representing 1.39% of its reported portfolio and ranking #19.
Has ORBIMED ADVISORS LLC been buying or selling CGON?
In the latest 13F filing (Q2 2026), ORBIMED ADVISORS LLC increased its position in CGON. The position peaked in Q3 2025 at 1.73M shares.
Which other funds hold CGON?
Other major institutional holders of CGON include RTW INVESTMENTS, LP, Decheng Capital LLC, TCG Crossover Management, LLC, among 52 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.